ABSTRACT
Introduction Lung cancer is the leading cause of cancer deaths in the world, and adenocarcinoma (LUAD) is its most prevalent subtype. Symptoms often appear in advanced disease when treatment options are limited. Identifying genetic risk factors will enable better identification of high-risk individuals.
Methods To identify LUAD risk genes, we performed a case-control association study for gene-level burden of rare, deleterious variants (RDVs) in germline whole-exome sequencing (WES) data of 1,083 LUAD patients and 7,650 controls, split into discovery and validation cohorts. Of these, we performed WES on 97 patients and acquired the rest from multiple public databases. We annotated all rare variants for pathogenicity conservatively, using ACMG guidelines and ClinVar curation, and investigated gene-level RDV burden using penalized logistic regression. All statistical tests were two-sided.
Results We discovered and replicated the finding that the burden of germline ATM RDVs was significantly higher in LUAD patients versus controls (ORcombined=4.6; p=1.7e-04; 95% CI=2.2–9.5; 1.21% of cases; 0.24% of controls). Germline ATM RDVs were also enriched in an independent clinical cohort of 1,594 patients from the MSK-IMPACT study (0.63%). Additionally, we observed that an Ashkenazi Jewish (AJ) founder ATM variant, rs56009889, was statistically significantly more frequent in AJ cases versus AJ controls in our cohort (ORcombined, AJ=2.7, p=6.9e-03, 95% CI=1.3–5.3).
Conclusions Our results indicate that ATM is a moderate-penetrance LUAD risk gene, and that LUAD may be part of the ATM-related cancer syndrome spectrum. Individuals with ATM RDVs are at elevated LUAD risk and can benefit from increased surveillance (particularly CT scanning), early detection and chemoprevention programs, improving prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from LUNGevity Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING: This work was supported by a grant from LUNGevity Foundation.
COMPETING FINANCIAL INTERESTS The authors declare no competing financial interests.
Data Availability
We downloaded the TCGA germline WES BAM files from National Cancer Institute Genomic Data Commons (GDC) data portal and the WES files for other samples from dbGaP. We will deposit the WES data for 97 samples that we sequenced in dbGaP.